These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30962322)

  • 1. Neutralization of BCL-2/X
    Zoeller JJ; Vagodny A; Taneja K; Tan BY; O'Brien N; Slamon DJ; Sampath D; Leverson JD; Bronson RT; Dillon DA; Brugge JS
    Mol Cancer Ther; 2019 Jun; 18(6):1115-1126. PubMed ID: 30962322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
    Zoeller JJ; Vagodny A; Daniels VW; Taneja K; Tan BY; DeRose YS; Fujita M; Welm AL; Letai A; Leverson JD; Blot V; Bronson RT; Dillon DA; Brugge JS
    Breast Cancer Res; 2020 Nov; 22(1):132. PubMed ID: 33256808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.
    Barok M; Le Joncour V; Martins A; Isola J; Salmikangas M; Laakkonen P; Joensuu H
    Cancer Lett; 2020 Mar; 473():156-163. PubMed ID: 31904483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine.
    Le Joncour V; Martins A; Puhka M; Isola J; Salmikangas M; Laakkonen P; Joensuu H; Barok M
    Mol Cancer Ther; 2019 Oct; 18(10):1721-1730. PubMed ID: 31292166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.
    Saatci Ö; Borgoni S; Akbulut Ö; Durmuş S; Raza U; Eyüpoğlu E; Alkan C; Akyol A; Kütük Ö; Wiemann S; Şahin Ö
    Oncogene; 2018 Apr; 37(17):2251-2269. PubMed ID: 29391599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer.
    Gedik ME; Saatci O; Oberholtzer N; Uner M; Akbulut Caliskan O; Cetin M; Aras M; Ibis K; Caliskan B; Banoglu E; Wiemann S; Üner A; Aksoy S; Mehrotra S; Sahin O
    Cancer Res; 2024 May; 84(9):1475-1490. PubMed ID: 38319231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.
    Yamashita-Kashima Y; Shu S; Osada M; Fujimura T; Yoshiura S; Harada N; Yoshimura Y
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):641-654. PubMed ID: 32997196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors.
    Pegram MD; Miles D; Tsui CK; Zong Y
    Clin Cancer Res; 2020 Feb; 26(4):775-786. PubMed ID: 31582515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.
    Hunter FW; Barker HR; Lipert B; Rothé F; Gebhart G; Piccart-Gebhart MJ; Sotiriou C; Jamieson SMF
    Br J Cancer; 2020 Mar; 122(5):603-612. PubMed ID: 31839676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired resistance to trastuzumab/pertuzumab or to T-DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728.
    Irie H; Kawabata R; Fujioka Y; Nakagawa F; Itadani H; Nagase H; Ito K; Uchida J; Ohkubo S; Matsuo K
    Cancer Sci; 2020 Jun; 111(6):2123-2131. PubMed ID: 32248641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.
    Jhaveri KL; Wang XV; Makker V; Luoh SW; Mitchell EP; Zwiebel JA; Sharon E; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
    Ann Oncol; 2019 Nov; 30(11):1821-1830. PubMed ID: 31504139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.
    Yamashita-Kashima Y; Yoshimura Y; Fujimura T; Shu S; Yanagisawa M; Yorozu K; Furugaki K; Higuchi R; Shoda J; Harada N
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):659-671. PubMed ID: 30659304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
    Al Rabadi LS; Cook MM; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI
    BMC Cancer; 2021 Oct; 21(1):1150. PubMed ID: 34706686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer.
    Wang L; Wang Q; Gao M; Fu L; Li Y; Quan H; Lou L
    Cancer Sci; 2018 Oct; 109(10):3305-3315. PubMed ID: 30076657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
    Yokoe T; Kurozumi S; Nozawa K; Ozaki Y; Maeda T; Yazaki S; Onishi M; Fujimoto A; Nakayama S; Tsuboguchi Y; Iwasa T; Sakai H; Ogata M; Terada M; Nishimura M; Onoe T; Masuda J; Kurikawa M; Isaka H; Hagio K; Shimomura A; Okumura Y; Futamura M; Shimokawa M; Takano T
    Breast Cancer; 2021 May; 28(3):581-591. PubMed ID: 33389616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development.
    Fujihara M; Shien T; Shien K; Suzawa K; Takeda T; Zhu Y; Mamori T; Otani Y; Yoshioka R; Uno M; Suzuki Y; Abe Y; Hatono M; Tsukioki T; Takahashi Y; Kochi M; Iwamoto T; Taira N; Doihara H; Toyooka S
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.
    English DP; Bellone S; Schwab CL; Bortolomai I; Bonazzoli E; Cocco E; Buza N; Hui P; Lopez S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Cancer Med; 2014 Oct; 3(5):1256-65. PubMed ID: 24890382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of T-DM1-resistant breast cancer cells.
    Sauveur J; Conilh L; Beaumel S; Chettab K; Jordheim LP; Matera EL; Dumontet C
    Pharmacol Res Perspect; 2020 Aug; 8(4):e00617. PubMed ID: 32583565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond.
    García-Alonso S; Ocaña A; Pandiella A
    Trends Cancer; 2020 Feb; 6(2):130-146. PubMed ID: 32061303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.